Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
11
MREO Quote, Financials, Valuation and Earnings
Last price:
$1.80
Seasonality move
:
-5.28%
Day range:
$1.68 - $1.78
52-week range:
$1.57 - $5.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.63x
Volume:
3.3M
Avg. volume:
3.2M
1-year change:
-57.21%
Market cap:
$278.3M
Revenue:
$10M
EPS (TTM):
-$0.35
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.01 | -100% | -87.66% | $7.32 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$11.1M | -$0.14 | -91.39% | -8.33% | $1.45 |
|
AUTL
Autolus Therapeutics PLC
|
$12.9M | -$0.23 | -80.39% | -10.73% | $9.86 |
|
BCYC
Bicycle Therapeutics PLC
|
$9.4M | -$0.93 | 0.73% | -20.58% | $26.27 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$92.4M | $0.09 | 2034.1% | -97.73% | $106.22 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
$1.75 | $7.32 | $278.3M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.27 | $1.45 | $71.6M | -- | $0.00 | 0% | 0.39x |
|
AUTL
Autolus Therapeutics PLC
|
$2.44 | $9.86 | $649.4M | -- | $0.00 | 0% | -- |
|
BCYC
Bicycle Therapeutics PLC
|
$7.78 | $26.27 | $538.8M | -- | $0.00 | 0% | 19.61x |
|
NCNA
NuCana PLC
|
$0.05 | $104.00 | $304.1K | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$104.74 | $106.22 | $8.9B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.029 | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
-211.44% | 3.289 | 50.03% | 1.57x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.256 | -- | 8.74x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.061 | -- | 14.57x |
|
NCNA
NuCana PLC
|
-- | -1.015 | -- | -- |
|
VRNA
Verona Pharma PLC
|
51.62% | 1.047 | 4.47% | 8.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$11M | -- | -- | -- | -$8.6M |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.4M | -$44.1M | -107.36% | -199.63% | -619.47% | -$67.8M |
|
AUTL
Autolus Therapeutics PLC
|
-$9M | -$65.2M | -49.92% | -49.92% | -643.43% | -$83.8M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$70M | -27.79% | -28.27% | -619.32% | -$87M |
|
NCNA
NuCana PLC
|
-- | -$3.5M | -- | -- | -- | -$4M |
|
VRNA
Verona Pharma PLC
|
$72.8M | -$10.3M | -51.07% | -85.84% | -8.34% | -$12.1M |
Mereo BioPharma Group PLC vs. Competitors
-
Which has Higher Returns MREO or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -653.18%. Mereo BioPharma Group PLC's return on equity of -- beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M -
What do Analysts Say About MREO or ADAP?
Mereo BioPharma Group PLC has a consensus price target of $7.32, signalling upside risk potential of 318.54%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.45 which suggests that it could grow by 437.5%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 ADAPAdaptimmune Therapeutics PLC2 4 0 -
Is MREO or ADAP More Risky?
Mereo BioPharma Group PLC has a beta of 0.403, which suggesting that the stock is 59.683% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.923%.
-
Which is a Better Dividend Stock MREO or ADAP?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or ADAP?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Mereo BioPharma Group PLC's net income of -$12.9M is higher than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 0.39x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$12.9M ADAPAdaptimmune Therapeutics PLC0.39x -- $7.3M -$47.6M
-
Which has Higher Returns MREO or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -781.13%. Mereo BioPharma Group PLC's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -49.92%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M -
What do Analysts Say About MREO or AUTL?
Mereo BioPharma Group PLC has a consensus price target of $7.32, signalling upside risk potential of 318.54%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 303.92%. Given that Mereo BioPharma Group PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is MREO or AUTL More Risky?
Mereo BioPharma Group PLC has a beta of 0.403, which suggesting that the stock is 59.683% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.813, suggesting its more volatile than the S&P 500 by 81.299%.
-
Which is a Better Dividend Stock MREO or AUTL?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or AUTL?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $9M. Mereo BioPharma Group PLC's net income of -$12.9M is higher than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$12.9M AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M
-
Which has Higher Returns MREO or BCYC?
Bicycle Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -608.94%. Mereo BioPharma Group PLC's return on equity of -- beat Bicycle Therapeutics PLC's return on equity of -28.27%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M -
What do Analysts Say About MREO or BCYC?
Mereo BioPharma Group PLC has a consensus price target of $7.32, signalling upside risk potential of 318.54%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $26.27 which suggests that it could grow by 237.7%. Given that Mereo BioPharma Group PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is MREO or BCYC More Risky?
Mereo BioPharma Group PLC has a beta of 0.403, which suggesting that the stock is 59.683% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.784%.
-
Which is a Better Dividend Stock MREO or BCYC?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BCYC?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $10M. Mereo BioPharma Group PLC's net income of -$12.9M is higher than Bicycle Therapeutics PLC's net income of -$60.8M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 19.61x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$12.9M BCYCBicycle Therapeutics PLC19.61x -- $10M -$60.8M
-
Which has Higher Returns MREO or NCNA?
NuCana PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- NCNANuCana PLC-- -$0.63 -- -
What do Analysts Say About MREO or NCNA?
Mereo BioPharma Group PLC has a consensus price target of $7.32, signalling upside risk potential of 318.54%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 207071.32%. Given that NuCana PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe NuCana PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 NCNANuCana PLC0 1 0 -
Is MREO or NCNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.403, which suggesting that the stock is 59.683% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.426, suggesting its more volatile than the S&P 500 by 42.561%.
-
Which is a Better Dividend Stock MREO or NCNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or NCNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$12.9M is lower than NuCana PLC's net income of -$3.1M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$12.9M NCNANuCana PLC-- -- -- -$3.1M
-
Which has Higher Returns MREO or VRNA?
Verona Pharma PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -21.4%. Mereo BioPharma Group PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -85.84%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- VRNAVerona Pharma PLC95.53% -$0.16 $468.3M -
What do Analysts Say About MREO or VRNA?
Mereo BioPharma Group PLC has a consensus price target of $7.32, signalling upside risk potential of 318.54%. On the other hand Verona Pharma PLC has an analysts' consensus of $106.22 which suggests that it could grow by 1.42%. Given that Mereo BioPharma Group PLC has higher upside potential than Verona Pharma PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 VRNAVerona Pharma PLC1 10 0 -
Is MREO or VRNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.403, which suggesting that the stock is 59.683% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.240, suggesting its less volatile than the S&P 500 by 76.016%.
-
Which is a Better Dividend Stock MREO or VRNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or VRNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $76.3M. Mereo BioPharma Group PLC's net income of -$12.9M is higher than Verona Pharma PLC's net income of -$16.3M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$12.9M VRNAVerona Pharma PLC-- -- $76.3M -$16.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
